Barnett S. Kramer

Barnett S. Kramer

Auto-generated profile, based on publicly available information

Barnett S. Kramer

National Institutes of Health

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Seminars in Oncology
Verified
Journal Article
Closed access
JCJennifer M. Croswell
Jennifer M. Croswell
DRDavid F. Ransohoff
David F. Ransohoff
BKBarnett S. Kramer
Barnett S. Kramer

28 February 2002 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
SBStuart Baker
Stuart Baker
BKBarnett S Kramer
Barnett S Kramer
SSSudhir Srivastava
Sudhir Srivastava
Recently many long-term prospective studies have involved serial collection and storage of blood or tissue specimens. This has spurred nested case-control studies that involve testing some specimens for various markers that might predict cancer. Until now there has been little guidance in statistical design and analysis of these studies. To develop statistical guidelines, we considered the purpose, the types of biases, and the opportunities for extracting additional information. The following guidelines: (1) For the clearest interpretation, statistics should be based on false and true positive rates – not odds ratios or relative risks (2) To avoid overdiagnosis bias, cases should be diagnosed as a result of symptoms rather than on screening. (3) To minimize selection bias, the spectrum of control conditions should be the same in study and target screening populations. (4) To extract additional information, criteria for a positive test should be based on combinations of individual markers and changes in marker levels over time. (5) To avoid overfitting, the criteria for a positive marker combination developed in a training sample should be evaluated in a random test sample from the same study and, if possible, a validation sample from another study. (6) To identify biomarkers with true and false positive rates similar to mammography, the training, test, and validation samples should each include at least 110 randomly selected subjects without cancer and 70 subjects with cancer. These guidelines ensure good practice in the design and analysis of nested case-control studies of early detection biomarkers.

1 February 2009 in Annual Review of Medicine
Verified
Journal Article
Closed access
BKBarnett S. Kramer
Barnett S. Kramer
JCJennifer Miller Croswell
Jennifer Miller Croswell
The concept of early detection of cancer holds great promise and intuitive appeal. However, powerful biases can mislead clinicians when evaluating the efficacy of screening tests by clinical observation alone. Selection bias, lead-time bias, length-biased sampling, and overdiagnosis are counterintuitive concepts with critical implications for early-detection efforts. This article explains these biases and other common confounders in cancer screening. The most direct and reliable way to avoid being led astray by intuitions is through the use of randomized controlled trials.

1 July 2004 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
BKBarnett S Kramer
Barnett S Kramer

4 June 2015
Verified
Book Chapter
Closed access
PDF file
SBStuart Baker
Stuart Baker
BKBarnett S. Kramer
Barnett S. Kramer